Immune complex-like moieties in immunoglobulin for intravenous use (IVIg) bind complement and enhance phagocytosis of human erythrocytes

Clinical and Experimental Immunology

Volumn 113, Issue 1, 1998, Pages 77-84

  Shoham Kessary, H ^a   Naot, Y ^a   Gershon, H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Autoimmunity; C'3; CR1; Erythrocyte sequestration; Immune complex

Indexed keywords

ALLOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3B; DIMER; FIBRINOGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; COMPLEMENT C3B; COMPLEMENT SYSTEM PROTEINS; DIMERIZATION; ERYTHROCYTES; FEMALE; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; MALE; MIDDLE AGED; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT 3B;

EID: 0031821633     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00624.x     Document Type: Article

References (35)

1. Mouthon L, Kaveri SV, Spalter SH et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104:3-9.
2. Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin: effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996;156:749-57.
3. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996;104:21-25.
4. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-81.
5. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144:1387-95.
6. Dietrich G, Kaveri SV, Kazatchkine MD. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992;22:1701-6.
7. Miletic VD, Frank MM. Complement immunoglobulin interactions. Curr Opin Immunol 1995;7:41-47.
8. Lutz HU, Stammler P, Fasler S. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem 1993;268:17418-26.
9. Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996;135:85-88.
10. Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991; 68 (Suppl.): 1430-6.
11. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells? Lancet 1983;23:193-5.
12. Mueller-Eckhardt C, Salama A, Mahn I, Kiefel V, Neuzner J, Graubner M. Luck of efficacy of high-dose intravenous immunoglobulin in autoimmune haemolytic anaemia: a clue to its mechanism. Scand J Haematol 1985;34:394-400.
13. Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced hemolysis in autoimmune hemolytic anemia treated with intravenous gammaglobulin. J Pediatr 1987;110:917-9.
14. Oda H, Honda A, Sugita K, Nakamura A, Nakajima H. High-dose intravenous intact IgG infusion in refractory autoimmune hemolytic anemia (Evans syndrome). J Pediatr 1985;107:744-6.
15. Thomas MJ, Mishah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood 1993;82:3789.
16. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986;26:410-2.
17. Moscow JA, Casper AJ, Kodis C, Fricke WA. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion 1987;27:248-9.
18. Shapiro S, Pilar T, Gershon H. Exposure to complement-bearing immune complexes enhances the in vitro sequestration of erythrocytes from young but not elderly donors. Clin Exp Immunol 1993;91:301-7.
19. Shapiro S, Kohn D, Miller B, Gershon H. Erythrocytes from young but not elderly donors can bind and degrade immune complex- and antibody-bound C3 in vitro. Clin Exp Immunol 1994;95:181-90.
20. Jepsen HH, Svehag SE, Jensenius JC, Sim RB. Release of immune complexes bound to erythrocyte complement receptor (CR1), with particular reference to the role of factor I. Scand J Immunol 1986;24:205-13.
21. Sherwood TA, Virella G. The binding of immune complexes to human red cells: complement requirements and fate of the RBC bound IC after interaction with human phagocyte cells. Clin Exp Immunol 1986:64:195-204.
22. Beutler E, West C, Blume KG. The removal of leukocytes and platelets from whole blood. J Lab Clin Med 1976;88:328-33.
23. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med 1982;156:205-16.
24. Gerdes J, Naiem M, Mason DY, Stein H. Human complement (C3b) receptors defined by a mouse monoclonal antibody. Immunol 1982;45:645-53.
25. Hogg N, Ross GD, Jones DB, Sahisarenko M, Walport MJ, Lachmann PJ. Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol 1984:14:236-43.
26. Sheiban E, Gershon H. The specific blocking of an IgG dependent erythrophagocytosis assay by protein G and ELISA determination of in situ bound IgG on erythrocytes of normal donors. J Immunol Methods 1990;135:139-46.
27. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993;44:237-42.
28. Bussel JB, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986;51:264-9.
29. Izui S. Autoimmune hemolytic anemia. Curr Opin Immunol 1994;6:926-30.
30. Roldan R, Roman J, Lopez D, Gonzalez J, Sanchez C, Martinez F. Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methylprednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 1994;23:218-9.
31. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82:633-5.
32. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-92.
33. Fries LF, Gaither TA, Hammer CH, Frank MM. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 1984;160:1640-55.
34. Kavai M, Moller Rasmussen J, Baatrup G, Zsindely A, Svehag S-E. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes. Scand J Immunol 1988;28:123-8.
35. Edberg JC, Tosic L, Wright EL, Sutherland WM, Taylor RP. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. J Immunol 1988:141:4258-65.